Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $73.47 million versus the consensus estimate of $67.7 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $260-270 million, versus the consensus of $270.5 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.